4 recruiting, 3 not yet recruiting, 1 completed. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Sjögren's Disease: new trials by email Literature Review of Sjögren's Disease trials Research Report on Sjögren's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease Part A - Placebo for IBI355, Part B -Telitacicept, PartB -Placebo for Telitacicept - Sjögren's Disease | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2026-10-15 | 2026-09-23 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body HBM7020 - Rheumatoid Arthritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 63 | 2026-09-24 | 2026-10-13 |
| A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease DDY391, Placebo - Sjögren's Disease | Phase 2 | Recruiting | Novartis Pharmaceuticals | 344 | 2026-08-24 | 2026-10-13 |
| Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease Telitacicept 160mg, Conventional treatment - Sjögren's Disease, Interstitial Lung Disease | Recruiting | Peking University People's Hospital | 60 | 2026-05-01 | 2026-09-28 | |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases XmAb657 - Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | Xencor, Inc. | 60 | 2026-02-24 | 2026-08-03 |
| a Salivary Cell-free RNA Liquid Biopsy Model for Non-invasive Diagnosis in Sjögren's Disease Sjögren's Disease | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 101 | 2026-01-01 | 2026-09-17 |
Sjogren's Syndrome (8) · Autoimmune Diseases (3) · Lupus Erythematosus, Systemic (3) · Scleroderma, Systemic (3) · Arthritis, Rheumatoid (2) · Lung Diseases, Interstitial (2) · Myositis (2) · Scleroderma, Diffuse (2) · Arthritis, Psoriatic (1) · Dermatomyositis (1) · Dry Eye Syndromes (1) · Lupus Nephritis (1) · Muscular Diseases (1) · Psoriasis (1)
Arthritis (8) · Connective Tissue Diseases (8) · Eye Diseases (8) · Immune System Diseases (8) · Joint Diseases (8) · Lacrimal Apparatus Diseases (8) · Mouth Diseases (8) · Musculoskeletal Diseases (8) · Rheumatic Diseases (8) · Salivary Gland Diseases (8) · Skin and Connective Tissue Diseases (8) · Stomatognathic Diseases (8) · Xerostomia (8) · Dry Eye Syndromes (7) · Arthritis, Rheumatoid (6)
telitacicept (2) · deucravacitinib (1)
Bristol-Myers Squibb (2) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Peking University People's Hospital (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Xencor, Inc. (1)
China (4) · Australia (3) · United States (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Netherlands (1) · Poland (1)
Yuan Jia (1)
2025 (1)